Overview

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Status:
Completed

Trial end date:
2015-06-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of AVL-292 as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM).

Phase:

Phase 1

Details

Lead Sponsor:

Celgene
Celgene Corporation

Collaborator:

The Leukemia and Lymphoma Society